



May 28, 2015.

To,
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051.

Respected Sir,

Scrip Code : KILITCH

Sub: OUTCOME OF THE BOARD MEETING HELD ON THURSDAY, MAY 28, 2015.

With reference to the above captioned subject, we wish to intimate your esteemed exchange that as decided in the Meeting of the Board of Directors of the Company held today, i.e. on Thursday, May 28, 2015 at its Administrative Office at Mumbai, for which intimation was already given to you, the Board of Directors has:

- Approved and taken on record the standalone and consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2015 along with the Auditors Report thereon.

OTHER MATTERS:


- Formulated and approved a Code of Practices and Procedures for fair disclosure of unpublished price sensitive information pursuant to newly enacted SEBI (Prohibition of Insider Trading) Regulations, 2015.
- Formulated and approved a Code of Conduct to regulate, monitor and report trading by its employees and other connected persons towards achieving compliance with the regulations pursuant to newly enacted SEBI (Prohibition of Insider Trading) Regulations, 2015.

The above intimation is given to you for your record.

Thanking You,

Yours faithfully,

For **KILITCH DRUGS (INDIA) LIMITED**


MUKUND MEHTA
MANAGING DIRECTOR
(DIN: 00147876)



KILITCH DRUGS (INDIA) LIMITED

STATEMENT OF STANDALONE & CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31ST MARCH 2015

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN. L24239MH1992PLC066718

Rs. In Lacs

PART I	Particulars	STANDALONE					CONSOLIDATED
		Quarter Ended		Year ended		Year ended	
Sr. No.		31-03-2015	31-12-2014	31-03-2014	31-03-2015	31-03-2014	31-03-2015
		Audited	Unaudited	Audited	Audited	Audited	Audited
1	Income from operations						
	(a) Net Sales/Income from operations(net of Excise)	322.40	360.81	633.57	1843.73	1421.49	1843.73
	(b) Other operating income	8.93	18.93	(20.31)	59.01	68.31	59.01
	Total income from Operations (Net)	331.32	379.74	613.26	1902.73	1489.80	1902.73
2	Expenses						
	(a) Cost of materials consumed	124.06	147.74	363.82	648.59	732.25	648.59
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(4.69)	13.42	25.76	53.02	(145.96)	53.02
	(c) Employee Benefit Expenses	74.32	75.94	90.08	312.80	285.76	312.80
	(d) Depreciation and Amortisation Expenses	19.18	57.98	44.94	185.39	143.97	185.39
	(e) Export Product Registration Charges	3.16	34.81	111.87	110.13	183.18	110.13
	(f) Other Expenses	304.57	211.81	405.53	946.27	813.41	959.72
	Total Expenses	520.60	541.69	1042.00	2256.20	2012.62	2269.65
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(189.28)	(161.95)	(428.74)	(353.47)	(522.82)	(366.92)
4	Other Income	71.24	70.54	174.86	269.02	629.12	272.08
5	Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)	(118.03)	(91.41)	(253.88)	(84.44)	106.29	(94.84)
6	Finance Costs	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit / (Loss) from ordinary activities before exceptional items (5-6)	(118.03)	(91.41)	(253.88)	(84.44)	106.29	(94.84)
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from ordinary activities before tax (7+8)	(118.03)	(91.41)	(253.88)	(84.44)	106.29	(94.84)
10	Tax Expenses						
	Current Tax	0.00	0.00	(60.00)	0.00	0.00	0.00
	Deferred Tax	8.69	(16.38)	(8.34)	(65.90)	(10.35)	(65.90)
	Tax Adjustments of Earlier years	0.00	0.00	(1.00)	0.00	(1.00)	0.00
11	Net Profit / (Loss) from ordinary activities after tax (9-10)	(126.73)	(75.03)	(184.54)	(18.55)	117.65	(28.94)
12	Extra Ordinary Items (net of tax expenses)	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit / (Loss) for the period (11+12)	(126.73)	(75.03)	(184.54)	(18.55)	117.65	(28.94)
14	Paid-Up equity share capital (Face Value Rs 10 per share)	1323.18	1323.18	1323.18	1323.18	1323.18	1323.18
15	Reserve excluding Revaluation Reserve [As per the latest Audited Balance Sheet]				10674.36	10699.65	10664.71
16.i	Earnings per share (before extra ordinary items) (F.V. of Rs.10/-each) (not annualised):						
	(a) Basic	(0.96)	(0.57)	(1.39)	(0.14)	0.89	(0.02)
	(b) Diluted	(0.96)	(0.57)	(1.39)	(0.14)	0.89	(0.02)
16.ii	Earnings per share (after extra ordinary items) (F.V. of Rs.10/-each) (not annualised):						
	(a) Basic	(0.96)	(0.57)	(1.39)	(0.14)	0.89	(0.02)
	(b) Diluted	(0.96)	(0.57)	(1.39)	(0.14)	0.89	(0.02)



PART II		OTHER INFORMATION FOR THE QUARTER & YEAR ENDED 31ST MARCH, 2015				
	Particulars	Quarter Ended			Year ended	
		31-03-2015	31-12-2014	31-03-2014	31-03-2015	31-03-2014
A	PARTICULARS OF SHAREHOLDING					
1	Public shareholding					
	a) Number of shares	4697655	4697655	4697655	4697655	4697655
	b) Percentage of shareholding	35.50	35.50	35.50	35.50	35.50
2	Promoters and Promoter Group Shareholding					
	a) Pledge / Encumbered					
	Number of shares	0.00	0.00	0.00	0.00	0.00
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)					
	Percentage of shares (as a % of the total share capital of the company)					
	b) Non- encumbered					
	Number of shares	8534173	8534173	8534173	8534173	8534173
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100	100	100	100	100
	Percentage of shares (as a % of the total share capital of the company)	64.50	64.50	64.50	64.50	64.50

B	INVESTOR COMPLAINTS	Quarter ended 31.03.2015
	Pending at the beginning of the Quarter	NIL
	Received during the quarter	2
	Disposed off during the quarter	2
	Remaining unresolved at the end of the quarter	NIL

Notes:

- The above results as reviewed by the audit committee have been taken on record by the Board of Directors at their meeting held on 28th May, 2015.
- During the quarter, the Company has operated only in one reportable segment i.e. Pharmaceuticals.
- The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods. The Figures of the last quarter are the balancing figures between audited figures in respect of the full financial year and published year to date figures upto the third quarter of the current financial year.
- The company has consolidated the Financial Statements of its subsidiary for the Financial year 2014-15, in line with the requirements of the Accounting Standard AS -21 [Consolidated Financial Statements]. The Company did not have any subsidiary upto F.Y. 2013-14. Accordingly, the consolidated figures of the previous year are not available/reported.
- Consequent to the enactment of the Companies Act, 2013 (the Act) and its applicability for the accounting year with effect from 1st April, 2014, the company has computed depreciation with reference to the estimated economic lives of fixed assets prescribed by the Schedule II to the Act or actual useful life. For the assets, whose life has been completed as above, the written down value net of residual value as at April 1, 2014 has been adjusted to retained earnings and in other cases the carrying value as at 1st April, 2014 has been depreciated over the remaining useful life of the assets and accordingly recognised in the above financial results.

Place : Mumbai
Date : 28th May, 2015



MUKUND MEHTA
Managing Director



KILITCH DRUGS (INDIA) LIMITED

STANDALONE AND CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN. L24239MH1992PLC066718

Rs. (In Lacs)

Particulars	Standalone		Consolidated
	As at 31st March, 2015	As at 31st March, 2014	As at 31st March, 2015
	[Rs.]	[Rs.]	[Rs.]
EQUITY AND LIABILITIES	(Audited)	(Audited)	(Audited)
Shareholders' funds			
Share capital	1,323.18	1,323.18	1323.18
Reserves and surplus	10,674.36	10,699.65	10664.71
Non-current liabilities			
Deferred tax liabilities (Net)	-	15.08	-
Current liabilities			
Short term Borrowings	-	-	0.1
Trade payables	235.52	468.03	239.12
Other current liabilities	391.16	353.26	391.53
Short-term provisions	54.64	47.70	54.64
TOTAL	12,678.86	12,906.90	12,673.28
ASSETS			
Non-current assets			
Fixed assets			
Tangible assets	934.25	927.33	934.25
Intangible assets	4.11	5.93	4.11
Non-current investments	4,715.56	119.70	4,715.56
Deferred tax Assets (Net)	50.82	-	50.82
Long-term loans and advances	2,309.99	2,268.62	2,293.75
Other non current assets	-	-	2.58
Current assets			
Current investments	2,466.87	3,916.33	2,466.87
Inventories	238.12	259.90	238.12
Trade receivables	1,262.30	863.39	1,262.30
Cash and Bank balances	498.02	4,385.26	498.11
Short-term loans and advances	192.55	153.95	199.69
Other current assets	6.26	6.48	7.12
TOTAL	12,678.86	12,906.90	12,673.28

Place: Mumbai,
Dated: 28th May, 2015



For and on Behalf of the Board

[Signature]
MUKUND MEHTA
(Managing Director)

